Skip to main content
Top
Published in: Clinical Research in Cardiology 12/2015

01-12-2015 | Original Paper

Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis

Authors: Sebastian Ewen, Markus R. Meyer, Bodo Cremers, Ulrich Laufs, Andreas G. Helfer, Dominik Linz, Ingrid Kindermann, Christian Ukena, Michel Burnier, Stefan Wagenpfeil, Hans H. Maurer, Michael Böhm, Felix Mahfoud

Published in: Clinical Research in Cardiology | Issue 12/2015

Login to get access

Abstract

Renal denervation can reduce blood pressure in patients with uncontrolled hypertension. The adherence to prescribed antihypertensive medication following renal denervation is unknown. This study investigated adherence to prescribed antihypertensive treatment by liquid chromatography–high resolution tandem mass spectrometry in plasma and urine at baseline and 6 months after renal denervation in 100 patients with resistant hypertension, defined as baseline office systolic blood pressure ≥140 mmHg despite treatment with ≥3 antihypertensive agents. At baseline, complete adherence to all prescribed antihypertensive agents was observed in 52 patients, 46 patients were partially adherent, and two patients were completely non-adherent. Baseline office blood pressure was 167/88 ± 19/16 mmHg with a corresponding 24-h blood pressure of 154/86 ± 15/13 mmHg. Renal denervation significantly reduced office and ambulatory blood pressure at 6-month follow-up by 15/5 mmHg (p < 0.001/p < 0.001) and 8/4 mmHg (p < 0.001/p = 0.001), respectively. Mean adherence to prescribed treatment was significantly reduced from 85.0 % at baseline to 80.7 %, 6 months after renal denervation (p = 0.005). The blood pressure decrease was not explained by improvements in adherence following the procedure. Patients not responding to treatment significantly reduced their drug intake following the procedure. Adherence was highest for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta blockers (>90 %) and lowest for vasodilators (21 %). In conclusion, renal denervation can reduce office and ambulatory blood pressure in patients with resistant hypertension despite a significant reduction in adherence to antihypertensive treatment after 6 months.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219. doi:10.1093/eurheartj/eht151 CrossRefPubMed Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219. doi:10.​1093/​eurheartj/​eht151 CrossRefPubMed
5.
7.
go back to reference Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA (2012) Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 126(25):2976–2982. doi:10.1161/CIRCULATIONAHA.112.130880 CrossRefPubMed Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA (2012) Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 126(25):2976–2982. doi:10.​1161/​CIRCULATIONAHA.​112.​130880 CrossRefPubMed
9.
go back to reference Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V (2013) Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 34(28):2132–2140. doi:10.1093/eurheartj/eht197 PubMedCentralCrossRefPubMed Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V (2013) Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 34(28):2132–2140. doi:10.​1093/​eurheartj/​eht197 PubMedCentralCrossRefPubMed
10.
go back to reference Azizi M, Sapoval M, Gosse P et al (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385(9981):1957–1965. doi:10.1016/S0140-6736(14)61942-5 CrossRefPubMed Azizi M, Sapoval M, Gosse P et al (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385(9981):1957–1965. doi:10.​1016/​S0140-6736(14)61942-5 CrossRefPubMed
12.
go back to reference Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383(9917):622–629. doi:10.1016/s0140-6736(13)62192-3 CrossRefPubMed Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383(9917):622–629. doi:10.​1016/​s0140-6736(13)62192-3 CrossRefPubMed
16.
18.
go back to reference Ewen S, Baumgarten T, Rettig-Ewen V, Mahfoud F, Griese-Mammen N, Schulz M, Böhm M, Laufs U (2015) Analyses of drugs stored at home by elderly patients with chronic heart failure. Clin Res Cardiol 104(4):320–327. doi:10.1007/s00392-014-0783-2 CrossRefPubMed Ewen S, Baumgarten T, Rettig-Ewen V, Mahfoud F, Griese-Mammen N, Schulz M, Böhm M, Laufs U (2015) Analyses of drugs stored at home by elderly patients with chronic heart failure. Clin Res Cardiol 104(4):320–327. doi:10.​1007/​s00392-014-0783-2 CrossRefPubMed
20.
go back to reference Tsioufis C, Mahfoud F, Mancia G, Redon J, Damascelli B, Zeller T, Schmieder RE (2014) What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention 9(9):1027–1035. doi:10.4244/EIJV9I9A175 PubMed Tsioufis C, Mahfoud F, Mancia G, Redon J, Damascelli B, Zeller T, Schmieder RE (2014) What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention 9(9):1027–1035. doi:10.​4244/​EIJV9I9A175 PubMed
21.
go back to reference Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants. Anal Bioanal Chem 400(1):79–88. doi:10.1007/s00216-010-4398-9 CrossRefPubMed Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants. Anal Bioanal Chem 400(1):79–88. doi:10.​1007/​s00216-010-4398-9 CrossRefPubMed
22.
go back to reference Helfer AG, Turcant A, Boels D, Ferec S, Lelievre B, Welter J, Meyer MR, Maurer HH (2015) Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC–HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. Drug Test Anal 7(5):368–375. doi:10.1002/dta.1682 CrossRefPubMed Helfer AG, Turcant A, Boels D, Ferec S, Lelievre B, Welter J, Meyer MR, Maurer HH (2015) Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC–HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. Drug Test Anal 7(5):368–375. doi:10.​1002/​dta.​1682 CrossRefPubMed
23.
26.
go back to reference Rosa J, Widimsky P, Tousek P et al (2015) Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the prague-15 study. Hypertension 65(2):407–413. doi:10.1161/hypertensionaha.114.04019 CrossRefPubMed Rosa J, Widimsky P, Tousek P et al (2015) Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the prague-15 study. Hypertension 65(2):407–413. doi:10.​1161/​hypertensionaha.​114.​04019 CrossRefPubMed
29.
go back to reference Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR (2001) Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 19(2):335–341CrossRefPubMed Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR (2001) Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 19(2):335–341CrossRefPubMed
Metadata
Title
Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis
Authors
Sebastian Ewen
Markus R. Meyer
Bodo Cremers
Ulrich Laufs
Andreas G. Helfer
Dominik Linz
Ingrid Kindermann
Christian Ukena
Michel Burnier
Stefan Wagenpfeil
Hans H. Maurer
Michael Böhm
Felix Mahfoud
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 12/2015
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-015-0905-5

Other articles of this Issue 12/2015

Clinical Research in Cardiology 12/2015 Go to the issue